Mesenchymal stromal cell Therapy - Cellcolabs Clinical
Alternative Names: Human allogeneic bone-marrow-derived mesenchymal stromal cell product - Cellcolabs; StromaForteLatest Information Update: 27 Oct 2023
At a glance
- Originator Karolinska University Hospital
- Developer Cellcolabs
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cardiovascular disorders; Musculoskeletal disorders; Osteoarthritis
Most Recent Events
- 16 Oct 2023 Phase-I/II clinical trials in Musculoskeletal disorders in Bahamas (Parenteral) (NCT06074783)
- 16 Oct 2023 Phase-I/II clinical trials in Osteoarthritis (Treatment-experienced) in United Arab Emirates (Parenteral) (NCT06084988)
- 07 Oct 2023 Phase-I/II clinical trials in Cardiovascular disorders (Treatment-experienced) in Bahamas (Parenteral) (NCT06087848)